Project Grant R50CA315355
Award Date 8/6/26
Completion Date 7/31/31
Dollars Obligated $119K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Wyoming, MI 49503, USA
Similar Awards
- The National Institutes of Health Office of the Director awarded the Van Andel Research Institute $190,764 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to develop and improve research software for DNA methylation and RNA sequencing analysis. The award funds a research software engineer in Dr. Hui Shen's laboratory to enhance existing bioinformatics tools. Specific deliverables include removing unused code from BISCUIT (a whole-genome bisulfite sequencing...
- The National Cancer Institute awarded New York University $149,190 on December 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research training in biomedical careers fundamental to the National Cancer Program. The recipient, doing business as New York University School of Medicine, will conduct mechanistic research on DNA methylation and its regulation by epigenetic histone modifications. The research addresses cancer-related aberrations in DNA methylation...
- The National Cancer Institute, part of the National Institutes of Health under the Department of Health and Human Services, awarded Duke University $302,524 on September 10, 2025, under the Cancer Research Manpower program (CFDA 93.398). The award funds a postdoctoral research fellowship (F32) to investigate the role of SMARCAL1, an annealing helicase, in promoting glioma cell proliferation and suppressing tumor-intrinsic inflammation in alternative lengthening of telomeres (ALT)–positive...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $688,073 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop computational approaches that reconstruct the evolutionary history of cancer metastases. The project, led by Dr. Peter Van Loo, applies molecular archeology of cancer methods—DNA sequencing-based approaches that infer tumor evolutionary history—to metastatic disease. The work will advance understanding of how...
- The National Cancer Institute, within the Department of Health and Human Services, awarded The University of Texas Southwestern Medical Center $426,828 on May 4, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing R21CA313397). The award funds research into JUMONJI KDM5 histone demethylase enzymes and their role in mediating resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer. The project tests sensitivity of CDK inhibitor-resistant cell...
- The National Cancer Institute awarded the University of Maryland, College Park $369,075 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop computational methods for reconstructing transposable element activity in cancer genomes using long-read sequencing and local assembly approaches. The project addresses a fundamental gap in cancer genomics: somatic transposition events—insertions where DNA sequences jump or copy themselves to new genomic locations—occur in...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $170,394 on July 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support postdoctoral research training in cancer epigenetics. The award funds research examining polycomb repressive complexes and chromatin remodeling in neuroendocrine lineage carcinomas, particularly the transformation of conventional prostate adenocarcinoma into small-cell neuroendocrine prostate cancer. The investigator will conduct...
- The National Cancer Institute awarded The University of Chicago $421,685 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate TET3 cytosine demethylase as a target for enhancing radiotherapy response in mismatch repair-proficient colorectal cancer. The project uses CRISPR loss-of-function models in colorectal cancer cell lines and syngeneic tumors to examine how TET3 disruption affects double-strand break repair kinetics, cytosolic DNA accumulation,...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $131,933 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support spatial and functional profiling of tumor evolution trajectories and microenvironment interactions in VHL-driven renal cancers. The project applies spatially resolved transcriptomics, genomic engineering, and multi-omics methodologies to create a comprehensive spatial atlas of treatment-resistant clear cell renal cell...
- The National Cancer Institute awarded Sloan-Kettering Institute For Cancer Research $263,073 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research identifying genetic factors mediating alternative lengthening of telomeres (ALT) in cancer. The research targets ALT, a recombination-based telomere maintenance mechanism present in 10–15 percent of cancers, particularly sarcomas and gliomas. The investigator will conduct three aims: examining how chromatin...